10th October 2022|News OptiBiotix launches highly effective low dose prebiotic to stimulate targeted gut microbial growth
21st September 2022|News OptiBiotix launches GoFigure® weight management range in India with Apollo Hospitals
6th July 2022|News OptiBiotix to exhibit award-winning microbiome modulation solutions at IFT Chicago
8th June 2022|News OptiBiotix builds on its leading microbiome presence after floating ProBiotix Health subsidiary on AQSE Growth Market
5th April 2022|Commercial Media, News Groundbreaking LPLDL® cholesterol study nominated for NutraIngredients award
3rd March 2022|Commercial Media, News Latest LPLDL® human intervention study from ProBiotix Health highlights ‘promising findings’ on cholesterol reduction
9th February 2022|Commercial Media, News OptiBiotix targets sports nutrition market with launch of LeanBiome™
8th February 2022|Commercial Media, News OptiBiotix signs exclusive sales and distribution agreement with leading Saudi pharma chain, Nahdi Medical Co
3rd February 2022|Commercial Media, News British Retail Consortium Accreditation backs OptiBiotix health and wellness solutions
19th January 2022|News, Scientific Media LPLDL® from ProBiotix Health showcases statistically significant reductions in multiple coronary heart disease biomarkers in hypercholesterolemic adults
